ANL — Adlai Nortye Group Ltd.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1944552 ·
Singapore
Last close
$9.48
Market Cap
$556.80M
52W High
$17.25
52W Low
$0.88
ADV30
322,060
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | — | — | — | — | 248,362,000 | 132,590,000 | 33,534,000 |
| Dec 2025 | — | — | — | — | 34,433,000 | 8,056,000 | 42,755,000 |
| Jun 2025 | — | — | — | — | 72,045,000 | 44,138,000 | 64,124,000 |
Balance + Analyst (yfinance extras)
Retained Earnings
$-470,182,000
Inventory
—
Receivables
$7,982,000
ST Investments
$100,227,000
EBIT TTM
—
Pretax Income TTM
—
Interest Exp TTM
—
Analysts
6
Yahoo Snapshot (yfinance, live)
Total Revenue
$18,056,000
EBITDA
$-21,650,500
Free Cash Flow
$-11,449,125
Enterprise Value
$773,376,640
Total Cash
$232,816,992
Total Debt
$26,701,000
Shares Out
58,734,604
Trailing EPS
$-0.66
Book Value
$3.34
ROE
-20.2%
ROA
-8.7%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 5,000,000 | -35,698,000 | -35,528,000 | 34,433,000 | 42,755,000 | -8,322,000 | -33,452,000 |
| Dec 2024 | 0 | -52,928,000 | -51,869,000 | 71,270,000 | 45,785,000 | 25,485,000 | -51,819,000 |
| Dec 2023 | 0 | -72,551,000 | -109,228,000 | 130,189,000 | 55,143,000 | 75,046,000 | -56,652,000 |
| Dec 2022 | 0 | -67,270,000 | -58,790,000 | 72,594,000 | 313,887,000 | -241,293,000 | -43,223,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.29
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ZVRA | ZEVRA THERAPEUTICS, INC. | $559.34M | $9.40 | — |
| WVE | Wave Life Sciences, Inc. | $560.13M | $2.84 | — |
| AVBP | ArriVent BioPharma, Inc. | $552.92M | $10.69 | — |
| CLYM | Climb Bio, Inc. | $574.46M | $9.78 | — |
| ACRS | Aclaris Therapeutics, Inc. | $536.11M | $3.38 | — |
News headlines (Yahoo Finance, 1h cache)
Adlai Nortye Announces Oral Presentation for AN4035 Program Update at the Upcoming 38th EORTC-NCI-AACR Symposium
2026-10-27 20:05 · Yahoo
4.8x P B? Adlai Nortye Group (ANL) On Its AN4035 Trial Progress
2026-09-15 17:12 · Yahoo
Adlai Nortye Enters into Clinical Collaboration with Lilly and Merck KGaA, Darmstadt, Germany to Evaluate Combination of AN4035 and Cetuximab
2026-10-15 11:00 · Yahoo
Is Adlai Nortye Ltd. Sponsored ADR (ANL) Stock Outpacing Its Medical Peers This Year?
2026-10-14 12:40 · Yahoo
Adlai Nortye Appoints Christopher Liu, PharmD, as Head of Investor Relations and Public Relations
2026-09-30 11:00 · Yahoo
Adlai Nortye Announces First Patient Dosed in Australia and U.S. FDA IND Clearance for AN4035, a First-in-Class Pan-RAS(ON) Inhibitor-Based ADC
2026-09-08 11:00 · Yahoo
These 2 ‘Monster Growth’ Stocks Aren’t Done Climbing, Say Analysts
2026-09-06 18:00 · Yahoo
Adlai Nortye Ltd. Reports Unaudited First Half 2026 Financial Results and Highlights Recent Operational Progress
2026-08-14 11:00 · Yahoo
Adlai Nortye Announces Clinical Trial Notification Submission and HREC Approval for the Phase I Clinical Trial of Pan-RAS(ON) Inhibitor ADC AN4035 in Australia
2026-08-03 11:00 · Yahoo
Adlai Nortye Announces First Patient Dosed in Intermittent Weekly Dosing Arm of Global Phase 1 Trial of Pan-RAS(ON) Inhibitor AN9025
2026-07-16 11:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.